NCT04027530View on ClinicalTrials.gov

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
Type 2 Diabetes MellitusDiabetic Kidney DiseaseDiabetic NephropathyRenal HypoxiaRenoprotectionSGLT2 InhibitorErtugliflozin
Interventions
DRUG

Ertugliflozin 15 mg

Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks

Trial Locations (1)

1081 HV

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT04027530 - Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study. | Biotech Hunter | Biotech Hunter